Aim: The nuclear export of most tumor suppressor proteins (TSPs) inactivates their anti-cancer functions. Exportin 1 (XPO1) is the exclusive nuclear exporter of nearly all TSPs. Multiple TSP pathways are altered in HN-SCC including p53, CDKN2A, pRB and others. Selinexor (KPT-330) is a novel, orally bioavailable, selective inhibitor of nuclear export (SINE) that blocks XPO1, leading to the nuclear accumulation and re-activation of TSPs. Selinexor has shown potent in vitro and in vivo activity in numerous models of solid tumors with squamous histology. Methods: Oral selinexor was given at 8-10 doses (2-3 times/week)/28-day cycle as part of an ongoing Phase 1 study in advanced solid tumors (KCP-330-002, NCT01607905). Response evaluation was done every 2 cycles (RECIST 1.1). Over 130 patients ( pts) were enrolled, including 17 pts with heavily pretreated HN-SCC with objectively progressive disease (PD) on study entry. Results: Seventeen pts with HN-SCC (14 M, 3 F; median age 56 yrs; ECOG PS 0/1: 4/ 13; median prior regimens: 2.6 (range 1-4)) received selinexor across 6 dose levels (23 to 65 mg/m 2 ). Grade 4 AEs included thrombocytopenia without bleeding in 3 pts. The most common AEs (Grade 1/2/3) include: fatigue (12%/41%/6%), nausea (41%/6%/ 6%), anorexia (12%/41%/0%), diarrhea (35%/12%/0%), weight loss (18%/24%/0%) and thrombocytopenia (18%/0%/12%). Supportive care with glucocorticoids, appetite stimulants and anti-emetics improved constitutional symptoms. Pharmacokinetics and pharmacodynamics showed dose-dependent increases in C max /AUC 0-inf and in XPO1 mRNA. Tumor biopsies showed nuclear localization of TSPs ( p53, FOXO3A, IκB) and apoptosis induction. Fourteen pts with PD on study entry were evaluable for efficacy. Nine patients (64%) had stable disease and 5 pts (36%) had progressive disease. 5 pts have remained on therapy for ≥4 months (4-13). Conclusions: Oral selinexor is generally well tolerated and can be administered over prolonged periods. Durable single agent disease control was observed in heavily pretreated HN-SCC pts. The recommended dose is 65 mg/m 2 twice weekly and a Phase 2 study in patients with HN-SCC is expected to begin in mid 2014. Disclosure: All authors have declared no conflicts of interest.
